Summary of Myriad Genetics, Inc. (NASDAQ:MYGN) Ratings

Myriad Genetics, Inc. (NASDAQ:MYGN) Corporate Logo
During Q2 2018 the big money sentiment decreased to 0.95. That’s change of 0.48, from 2018Q1’s 1.43. 25 investors sold all, 80 reduced holdings as Myriad Genetics, Inc. ratio worsened. 65 rose positions while 35 funds acquired positions. Funds hold 71.11 million shares thus 1.16% less from 2018Q1’s 71.94 million shares.
United Kingdom-based Pictet Asset Management has invested 0.02% in Myriad Genetics, Inc. (NASDAQ:MYGN). Thrivent Financial For Lutherans holds 2.86M shs or 0.35% of its capital. Credit Suisse Ag accumulated 67,939 shs or 0% of the stock. Mackay Shields Limited Company holds 24,102 shs. Mitsubishi Ufj Trust Banking Corporation has invested 0.03% in Myriad Genetics, Inc. (NASDAQ:MYGN). Cs Mckee L P reported 0.12% stake. Fisher Asset Mgmt Ltd Llc stated it has 118,086 shs. The New York-based Bnp Paribas Arbitrage Sa has invested 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Daiwa Group has invested 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Element Cap Limited Liability Company holds 0.01% of its capital in Myriad Genetics, Inc. (NASDAQ:MYGN) for 7,913 shs. Disciplined Growth Invsts Mn owns 1.30 million shs. Washington-based Parametric Associate has invested 0.01% in Myriad Genetics, Inc. (NASDAQ:MYGN). Profund Advsrs Limited Liability has 37,025 shs for 0.06% of their capital. Millennium Mngmt Ltd Liability Com has invested 0.02% in Myriad Genetics, Inc. (NASDAQ:MYGN). 376,515 are owned by Wells Fargo And Mn.

Myriad Genetics, Inc. registered $13.47 million net activity with 0 insider purchases and 6 selling transactions since June 5, 2018. 30,000 shs were sold by GILBERT WALTER PHD, worth $1.19M. On Wednesday, July 11 a trade for 50,000 shs valued at $2.17 million was made by LANCHBURY JERRY S. Capone Mark Christopher also sold $3.28 million worth of Myriad Genetics, Inc. (NASDAQ:MYGN) shs. MARSH RICHARD M sold $3.03 million worth of stock or 70,672 shs. On Wednesday, June 6 LANGER DENNIS sold $801,594 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) or 20,369 shs.

Myriad Genetics, Inc. (NASDAQ:MYGN) Ratings Coverage

In total 7 analysts cover Myriad Genetics (NASDAQ:MYGN). “Buy” rating has 2, “Sell” are 2, while 3 are “Hold”. (NASDAQ:MYGN) has 29% bullish analysts. 12 are the (NASDAQ:MYGN)’s ratings reports on Dec 8, 2018 according to StockzIntelligence Inc. On Tuesday, September 11 the stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Underweight” rating by Barclays Capital. On Wednesday, August 22 the rating was maintained by Barclays Capital with “Equal-Weight”. On Wednesday, October 10 the firm has “Overweight” rating given by PiperJaffray. In Wednesday, October 10 report Morgan Stanley maintained it with “Overweight” rating and $54 target. On Monday, July 16 the company was maintained by Bank of America. On Friday, November 30 the firm has “Neutral” rating given by Goldman Sachs. On Wednesday, July 11 the firm earned “Overweight” rating by Morgan Stanley. In Tuesday, August 28 report Leerink Swann maintained it with “Market Perform” rating and $49 target. On Wednesday, August 22 Morgan Stanley maintained Myriad Genetics, Inc. (NASDAQ:MYGN) with “Overweight” rating. On Wednesday, August 22 Bank of America maintained Myriad Genetics, Inc. (NASDAQ:MYGN) with “Underperform” rating. Listed here are Myriad Genetics, Inc. (NASDAQ:MYGN) PTs and latest ratings.

30/11/2018 Broker: Goldman Sachs Old Rating: Sell New Rating: Neutral Old Target: $28 New Target: $32 Upgrade
05/11/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Hold Old Target: $37 New Target: $43 Maintain
10/10/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $51 New Target: $54 Maintain
10/10/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Overweight Old Target: $38 New Target: $53 Upgrade
11/09/2018 Broker: Barclays Capital Old Rating: Underweight New Rating: Underweight Old Target: $30 New Target: $25 Maintain
05/09/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $38 New Target: $30 Downgrade
28/08/2018 Broker: Leerink Swann Old Rating: Market Perform New Rating: Market Perform Old Target: $35 New Target: $49 Maintain
22/08/2018 Broker: Bank of America Old Rating: Underperform New Rating: Underperform Old Target: $31 New Target: $34 Maintain
22/08/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $35 New Target: $38 Maintain
22/08/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $47 New Target: $49 Maintain

Ticker’s shares touched $31.51 during the last trading session after 1.93% change.Myriad Genetics, Inc. is uptrending after having risen 45.52% since December 8, 2017. MYGN has 974,980 volume or 8.03% up from normal. The stock outperformed the S&P 500 by 29.90%.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide.The firm is valued at $2.36 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.The P/E ratio is 44.51. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

For more Myriad Genetics, Inc. (NASDAQ:MYGN) news announced recently go to: Nasdaq.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4 – Nasdaq” announced on August 22, 2018, “Myriad announces new laboratory agreement with Pfizer – Seeking Alpha” on October 10, 2018, “After-Hours Earnings Report for August 21, 2018 : KEYS, JKHY, URBN, PSTG, MYGN, LZB, GSM, SMCI, RRGB – Nasdaq” with a publish date: August 21, 2018, “Factors of Influence in 2018, Key Indicators and Opportunity within Dillard’s, Biohaven Pharmaceutical Holding, HTG Molecular Diagnostics, Strongbridge Biopharma, Myriad Genetics, and Beazer Homes — New Research Emphasizes Economic Growth – Nasdaq” and the last “Myriad Announces New GeneSight® Study Published in Personalized Medicine – GlobeNewswire” with publication date: September 26, 2018.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.